Search tips
Search criteria 


Logo of bmjcrBMJ Case ReportsVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
BMJ Case Rep. 2010; 2010: bcr0420102919.
Published online 2010 October 28. doi:  10.1136/bcr.04.2010.2919
PMCID: PMC3029882
Novel treatment (new drug/intervention; established drug/procedure in new situation)

Omalizumab for severe atopic keratoconjunctivitis


A 35-year-old patient received omalizumab (300 mg twice a month) for 2 years for a severe atopic keratoconjunctivitis (AKC) in order to reduce the risk for steroid-induced keratitis. After 4 months, quality of life and ocular symptoms improved, and the use of oral steroids was strongly reduced. The treatment was well tolerated. This observation suggests that omalizumab may be a good option for the treatment of severe AKC, especially to avoid side effects of immunosuppressive treatments, as suggested for other allergic diseases. Specific trials should be designed for allergic eye diseases.

Articles from BMJ Case Reports are provided here courtesy of BMJ Group